Power3 Medical Products, Inc. (OTC:PWRM)
PWRM recently delivered four poster presentations at the 2010 ICAD. These presentations discussed PWRM’s diagnostic test, NuroPro, and focused on PWRM’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.
“In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosisAC and drug response to improve the treatment of Alzheimer’s disease,” stated Dr. Ira L. Goldknopf, PWRM ’s President & Chief ScACientific Officer. “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
“We are pleased that our blood tests specifically diagnose Alzheimer’s in patients, both pre- and post-treatment,” commented Helen R. Park, MS, CEO of PWRM, “and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii.”
“We are within striking distance of realizing an Alzheimer’s clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions,” added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.
Apollo Investment Corporation (Nasdaq:AINV) on Thursday November 4, 2010 said its third-quarter profit fell 38 percent as it exited from underperforming investments. For the three months ended Sept. 30, the closed-end investment company posted net income of $68.2 million, or 35 cents per share, compared with $109.2 million, or 71 cents per share, in the year-ago quarter.
Apollo Investment Corporation is business development company and operates as a closed-end management investment company. The company invests in middle market companies.
First Niagara Financial Group Inc. (Nasdaq:FNFG) announced that investors will have an opportunity to listen to a webcast of the Company's strategy and outlook as it presents at the Sandler O'Neill + Partners, L.P. East Coast Financial Services Conference at approximately 8:20 a.m. Eastern Time on Thursday, November 11, 2010.
First Niagara Financial Group, Inc., through its wholly owned subsidiary, First Niagara Bank, N.A., has $21 billion in assets, 256 branches and $13 billion in deposits. First Niagara Bank is a multi-state community-oriented bank with about 3,800 employees providing financial services to individuals, families and businesses.
Hercules Technology Growth Capital, Inc. (Nasdaq:HTGC) the leading specialty finance company devoted to addressing the capital needs of venture capital and private equity-backed companies in the technology, clean technology, and life science industries at all stages of development, announced that it has priced its public offering of 6,AC250,000 shares of its common stock at an offering price of $10.00 per share, raising $62.5 million of gross proceeds. Hercules also granted the underwriters an option to purchase up to an additional 937,500 shares of common stock to cover over-allotments, if any. The offering is subject to customary closing conditions and is expected to close on November 16, 2010.
Hercules Technology Growth Capital, Inc. is a NASDAQ traded specialty finance firm providing customized loans to public and private companies in the technology, clean technology, and life science industries, at all stages of development.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).